Literature DB >> 14662430

Part II: testicular cancer--management of advanced disease.

Robert H Jones1, Paul A Vasey.   

Abstract

Up to 80% of metastatic germ-cell tumours are curable with conventional chemotherapy. The combination of cisplatin, bleomycin, and etoposide has become the gold standard in this disease. Patients can be divided into good, intermediate, and poor prognosis groups. For those patients with good prognostic features, cure rates reach 90% and attempts have been made to reduce toxic effects of treatment while maintaining efficacy. Patients that relapse require salvage treatment. This can involve the incorporation of drugs such as ifosfamide and taxol into conventional protocols or the use of high-dose chemotherapy with stem-cell transplants. Patients with poor prognosis disease are much more likely to fail conventional chemotherapy and are candidates for dose-intensive protocols or transplants as first-line treatment. Although the results obtained in treating metastatic germ-cell tumours are superior to those with other solid tumour types, there are still many areas that require further improvement.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14662430     DOI: 10.1016/s1470-2045(03)01279-8

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  15 in total

1.  Prognostic impact of bleomycin pulmonary toxicity on the outcomes of patients with germ cell tumors.

Authors:  Yuki Maruyama; Takuya Sadahira; Yosuke Mitsui; Motoo Araki; Koichiro Wada; Ryuta Tanimoto; Yasuyuki Kobayashi; Masami Watanabe; Toyohiko Watanabe; Yasutomo Nasu
Journal:  Med Oncol       Date:  2018-04-26       Impact factor: 3.064

2.  Retroperitoneal lymph node dissection for metastatic germ cell tumours.

Authors:  N Haldipur; S Devaraj; A Shehata; A K Lewis; M O Smith; M Hatton; A Nassef; J D Beard
Journal:  Ann R Coll Surg Engl       Date:  2011-05       Impact factor: 1.891

Review 3.  Recent advances in the biology of germ cell tumors: implications for the diagnosis and treatment.

Authors:  P Chieffi; S Chieffi; R Franco; A A Sinisi
Journal:  J Endocrinol Invest       Date:  2012-11-12       Impact factor: 4.256

4.  p53 inactivation by MDM2 and MDMX negative feedback loops in testicular germ cell tumors.

Authors:  Baozong Li; Qian Cheng; Zhenyu Li; Jiandong Chen
Journal:  Cell Cycle       Date:  2010-04-01       Impact factor: 4.534

Review 5.  Systemic therapy for primary and extragonadal germ cell tumors: prognosis and nuances of treatment.

Authors:  Bilal A Siddiqui; Miao Zhang; Louis L Pisters; Shi-Ming Tu
Journal:  Transl Androl Urol       Date:  2020-01

6.  Testicular Germ Cell Tumors: A Paradigm for the Successful Treatment of Solid Tumor Stem Cells.

Authors:  Caryl J Giuliano; Sarah J Freemantle; Michael J Spinella
Journal:  Curr Cancer Ther Rev       Date:  2006-08-01

7.  Epidemiological pattern and time trends in testicular germ-cell tumors: a single institution 20-year experience.

Authors:  Jorge Molina Saera; Jorge Aparicio Urtasun; Roberto Díaz Beveridge; Laura Palomar Abad; Alejandra Giménez Ortiz; José Ponce Lorenzo; Joaquín Montalar Salcedo
Journal:  Clin Transl Oncol       Date:  2006-08       Impact factor: 3.405

Review 8.  [Aftercare in testicular cancer is worthwhile. Recurrences are curable].

Authors:  T S Pottek; K-P Dieckmann
Journal:  Urologe A       Date:  2005-09       Impact factor: 0.639

9.  New perspective on molecular markers as promising therapeutic targets in germ cell tumors.

Authors:  Paolo Chieffi
Journal:  Intractable Rare Dis Res       Date:  2016-05

Review 10.  Update on epidemiologic considerations and treatment trends in testicular cancer.

Authors:  Solomon L Woldu; Aditya Bagrodia
Journal:  Curr Opin Urol       Date:  2018-09       Impact factor: 2.309

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.